Clinical trial NCT03765944: Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets
Official title: A Single Dose, Randomized, Open-label, 2-Period, 2-way Crossover, Bioequivalence Study of Sirolimus Granules and Sirolimus Tablets in Japanese Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Bioequivalence Study
Lead sponsor: Nobelpharma
Sponsor class: INDUSTRY
First posted: 2018-12-05
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this study is to evaluate the bioequivalece of NPC-12 granules in compare with NPC-12T tablets in Japanese healthy Adults


Eligibility criteria: Inclusion Criteria:

1. Japanese healthy subjects aged 20 to 39 years of age
2. Subjects with BMI ≥ 18.5 kg/m2 and \< 25.0 kg/m2
3. Subjects who are considered by the investigator as suitable for participation in the trial from lab test results at screening
4. Subjects who are considered by the investigator as suitable for participation in the trial from lab test results on the day before administration
5. Subjects who write informed consent
6. Subjects who are able to comply with the study requirements during the study period

Exclusion Criteria:

1. Subjects who have a history of hypersensitivity to sirolimus or sirolimus derivative
2. Subjects who have a history of hypersensitivity or allergies to other drug
3. SUbjects who have an acute or chronic infectious diseases
4. Subjects who have a current or a history of disease which is considered inappropriate to be involved in the study, or who has any current disease to require treatments
5. Subjects who have diagnosed with alcoholism or a history of alcoholism
6. Subjects who have an abnormal findings (pneumonia, etc) from the result of chest CT at screening
7. Subjects who have been administered other investigational drug within 12 weeks before the initial administration
8. Subjects who have performed blood collection or donation as follows

   * Collected or donated 200 ml or more whole blood within 4 weeks before the initial administration
   * Male subject; collected or donated more than 400 mL whole blood within 12 weeks before the initial administration
   * Female subjects; collected or donated more than 400 mL whole blood within 16 weeks before the initial administration
   * Collected or donated blood component within 2 weeks before the initial administration
9. Subjects who have positive results for HBs antigen, HBs antibody, HBc antibody, HCV antibody, HIV antigen/antibody, or syphilis
10. Subjects who received any non-prescription or prescription drug within 12 weeks before the initial administration
11. Subjects who are pregnant/lactating, or do not agree to contraception during the period from the screening until 8 weeks after the final administration due to planning to become pregnant
12. Subjects who cannot speak, read and write in Japanese
13. Subjects who are considered by the investigator as unsuitable for participation in the trial

Primary outcomes:
measure: Blood sirolimus concentration
timeFrame: Pre-dose and post-dose (0.5, 1, 1.5, 2, 4, 8, 12, 18, 24, 48 and 72 hours)
Secondary outcomes:
Other outcomes:
Locations:
city: Matsudo
country: Japan
facility: Clinique Soigner
state: Chiba
Study officials:
References: